Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17118684 | Multiplexed Genome Editing | December 2020 | July 2024 | Allow | 43 | 3 | 0 | Yes | No |
| 17056352 | PARTIALLY CURED CONTACT LENS-TYPE AMNIOTIC MEMBRANE DRESSING AND METHOD OF MANUFACTURING SAME | November 2020 | June 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17055969 | MERKEL CELL POLYOMAVIRUS T ANTIGEN-SPECIFIC TCRS AND USES THEREOF | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17050949 | Use of Lentivector-Transduced T-RAPA Cells for Amelioration of Lysosomal Storage Disorders | October 2020 | October 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17076721 | COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF A FUSION PROTEIN AND RIBONUCLEIC ACID | October 2020 | July 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 17069896 | SAFE IMMUNO-STEALTH CELLS | October 2020 | May 2024 | Abandon | 43 | 7 | 1 | Yes | No |
| 17046287 | Recombinant PD-L1 Peptides and Methods of Use | October 2020 | February 2024 | Allow | 40 | 1 | 0 | No | No |
| 17044673 | IFN-beta Reporter System for Primary Cells | October 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17038482 | ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF GENETIC HEARING LOSS | September 2020 | October 2024 | Allow | 49 | 2 | 1 | Yes | No |
| 17020997 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | September 2020 | October 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17002460 | CNS DELIVERY OF MRNA AND USES THEREOF | August 2020 | February 2024 | Allow | 42 | 2 | 1 | Yes | Yes |
| 17001277 | ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY | August 2020 | July 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16993009 | RECOMBINOGENIC NUCLEIC ACID STRANDS IN SITU | August 2020 | August 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16937530 | Regeneration of a Functional Pulmonary Vascular Bed | July 2020 | May 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 16928151 | UNIVERSAL DONOR CELLS | July 2020 | November 2020 | Allow | 4 | 1 | 0 | No | No |
| 16928140 | UNIVERSAL DONOR CELLS | July 2020 | April 2021 | Allow | 9 | 2 | 0 | Yes | No |
| 16928158 | UNIVERSAL DONOR CELLS | July 2020 | April 2021 | Allow | 9 | 1 | 0 | No | No |
| 16912342 | METHOD FOR PRODUCING RENAL PROGENITOR CELLS | June 2020 | April 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16908947 | INDUCIBLE DISEASE MODELS METHODS OF MAKING THEM AND USE IN TISSUE COMPLEMENTATION | June 2020 | September 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16904909 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | June 2020 | January 2023 | Allow | 31 | 0 | 1 | Yes | No |
| 16902541 | STEM CELL CONDITIONED MEDIA AND METHODS OF PRODUCING THE SAME | June 2020 | November 2024 | Abandon | 53 | 3 | 1 | Yes | No |
| 16895065 | Materials and Methods for Producing Animals With Short Hair | June 2020 | June 2024 | Abandon | 48 | 2 | 1 | No | No |
| 15930781 | GENERATION AND CORRECTION OF A HUMANIZED MOUSE MODEL WITH A DELETION OF DYSTROPHIN EXON 44 | May 2020 | April 2023 | Abandon | 35 | 1 | 1 | Yes | No |
| 16848772 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | April 2020 | March 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16847597 | Methods for Enriching Pluripotent Stem Cell-Derived Cardiomyocyte Progenitor Cells and Cardiomyocyte Cells based on SIRPA Expression | April 2020 | May 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16650863 | Isolated Recombinant Oncolytic Adenoviruses, Pharmaceutical Compositions, and Uses Thereof for Drugs for Treatment of Tumors and/or Cancers | March 2020 | June 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16820066 | THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY | March 2020 | February 2023 | Allow | 35 | 1 | 0 | No | No |
| 16642582 | METHODS AND COMPOSITIONS FOR TREATING CONE-ROD RETINAL DYSTROPHY | February 2020 | June 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16606294 | REAGENT FOR DIFFERENTIATING SOMATIC CELLS INTO ALVEOLAR EPITHELIAL CELLS, AND USE OF SAID REAGENT | January 2020 | March 2023 | Allow | 41 | 2 | 1 | No | No |
| 16752406 | GENE THERAPY TREATMENT OF ATRIAL FIBRILLATION | January 2020 | August 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16632115 | COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR CARDIOMETABOLIC DISEASE | January 2020 | July 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16743968 | REVERSING THE EFFECTS OF THE TUMOR MICROENVIRONMENT USING CHIMERIC CYTOKINE RECEPTORS | January 2020 | March 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16725081 | VIRAL VECTORS FOR THE TREATMENT OF RETINAL DYSTROPHY | December 2019 | March 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16720142 | COMPOSITIONS AND METHODS FOR INDUCED BROWN FAT DIFFERENTIATION | December 2019 | May 2023 | Allow | 40 | 1 | 1 | No | No |
| 16711086 | CELL POTENCY ASSAY | December 2019 | September 2023 | Abandon | 45 | 2 | 1 | Yes | No |
| 16708655 | Multiplexed Genome Editing | December 2019 | October 2020 | Allow | 10 | 1 | 0 | No | No |
| 16698682 | THERAPEUTIC COMPOSITIONS AND METHODS OF USE FOR TREATING CANCER | November 2019 | February 2024 | Allow | 51 | 3 | 0 | Yes | No |
| 16615941 | GENE THERAPY FOR TREATING PEROXISOMAL DISORDERS | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16690320 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | November 2019 | April 2020 | Allow | 5 | 1 | 0 | Yes | No |
| 16612288 | TOOLS AND METHODS FOR GENOME EDITING ISSATCHENKIA ORIENTALIS AND OTHER INDUSTRIALLY USEFUL YEAST | November 2019 | January 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16673119 | NON-HUMAN ANIMALS HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE | November 2019 | February 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16672042 | GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO | November 2019 | May 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16666286 | INDUCED PLURIPOTENT STEM CELLS (IPSCS) AND APPLICATIONS THEREOF | October 2019 | May 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16659110 | INDUCED PLURIPOTENT CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF MYELIN DISORDERS | October 2019 | July 2024 | Allow | 57 | 4 | 0 | No | No |
| 16598960 | DISULFIDE BOND STABILIZED POLYPEPTIDE COMPOSITIONS AND METHODS OF USE | October 2019 | April 2021 | Allow | 18 | 2 | 1 | Yes | No |
| 16596164 | TARGETED DISRUPTION OF A CSF1-DAP12 PATHWAY MEMBER GENE FOR THE TREATMENT OF NEUROPATHIC PAIN | October 2019 | October 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16497412 | Genetic Construct | September 2019 | March 2024 | Abandon | 54 | 4 | 1 | Yes | No |
| 16573254 | MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF | September 2019 | August 2022 | Allow | 35 | 1 | 2 | No | No |
| 16494143 | TREATMENT OF RETINITIS PIGMENTOSA | September 2019 | February 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16493340 | SYNTHETIC PROMOTERS | September 2019 | February 2023 | Allow | 41 | 2 | 1 | No | No |
| 16492950 | NOVEL INTEGRATION SITES AND USES THEREOF | September 2019 | December 2023 | Allow | 51 | 5 | 1 | Yes | No |
| 16563193 | FACTOR IX GENE THERAPY | September 2019 | January 2022 | Allow | 29 | 1 | 0 | No | No |
| 16563089 | ENDOGENOUS RETROVIRUS TRANSCRIPTION AS A MARKER FOR PRIMATE NAIVE PLURIPOTENT STEM CELLS | September 2019 | March 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16563553 | UNIVERSAL DONOR CELLS | September 2019 | June 2020 | Allow | 9 | 1 | 1 | Yes | No |
| 16562958 | ENGINEERING MESODERMAL PRECURSOR CELL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF PERFUSION DISORDERS | September 2019 | April 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16546070 | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS | August 2019 | March 2022 | Allow | 31 | 1 | 1 | No | No |
| 16542099 | NOVEL RECOMBINANT HBV REPORTER SYSTEM | August 2019 | October 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16540960 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES | August 2019 | July 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16485148 | PRODUCTION METHOD FOR ARTIFICIAL PLURIPOTENT STEM CELLS | August 2019 | August 2023 | Abandon | 48 | 3 | 1 | No | No |
| 16484311 | GENE THERAPY | August 2019 | September 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16483668 | MATERIALS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS | August 2019 | March 2023 | Allow | 44 | 2 | 1 | Yes | No |
| 16531351 | Multiplexed Genome Editing | August 2019 | March 2021 | Allow | 20 | 3 | 1 | Yes | No |
| 16511913 | AAV Vectors Targeted to Oligodendrocytes | July 2019 | April 2024 | Allow | 57 | 5 | 1 | Yes | No |
| 16471808 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SOMATIC CELLS INTO INDUCED VASCULOGENIC CELLS | June 2019 | March 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16436723 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC PD-1 | June 2019 | October 2021 | Allow | 29 | 3 | 1 | Yes | No |
| 16435198 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD27 | June 2019 | December 2020 | Allow | 18 | 2 | 1 | Yes | No |
| 16428941 | Genetically Modified Non-Human Animal With Human Or Chimeric PD-L1 | May 2019 | October 2020 | Allow | 17 | 2 | 1 | Yes | No |
| 16464682 | PDL1 BLOCK CAR-T TRANSGENIC VECTOR FOR SUPPRESSING IMMUNE ESCAPE, PREPARATION METHOD THEREOF, AND APPLICATION OF THE SAME | May 2019 | May 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16464478 | SYNPI, A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN INTERNEURONS | May 2019 | December 2022 | Abandon | 42 | 2 | 1 | No | No |
| 16463829 | CONTROLLABLE TRANSCRIPTION | May 2019 | January 2023 | Allow | 43 | 2 | 1 | Yes | Yes |
| 16418063 | Extracellular Matrix Tissue Prostheses | May 2019 | June 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16417225 | Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use | May 2019 | July 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16409052 | RODENT MODELS WITH AUTISTIC FEATURES | May 2019 | May 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16346003 | Rat Models for CMT2A That Develop a Progressive Neuropathy | April 2019 | July 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16346077 | HUMAN ANTIBODY-PRODUCING NON-HUMAN ANIMAL AND METHOD FOR PREPARING HUMAN ANTIBODIES USING SAME | April 2019 | April 2024 | Allow | 59 | 5 | 1 | Yes | No |
| 16397006 | EXPRESSION CASSETTE | April 2019 | November 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16396262 | AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect Subjects from Diabetes or Obesity | April 2019 | August 2021 | Allow | 28 | 1 | 1 | Yes | No |
| 16388924 | USES OF INDUCED NEURAL STEM CELLS DERIVED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS | April 2019 | April 2023 | Allow | 48 | 4 | 1 | Yes | No |
| 16387664 | NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | April 2019 | April 2021 | Allow | 24 | 0 | 1 | Yes | No |
| 16341704 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM | April 2019 | August 2023 | Allow | 52 | 4 | 1 | Yes | No |
| 16340999 | SELF-LIMITING CAS9 CIRCUITRY FOR ENHANCED SAFETY (SLICES) PLASMID AND LENTIVIRAL SYSTEM THEREOF | April 2019 | February 2022 | Abandon | 35 | 0 | 1 | No | No |
| 16374369 | METHODS AND COMPOSITIONS TO REDUCE OXIDATIVE STRESS | April 2019 | April 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16369174 | Extracellular Matrix Structures | March 2019 | June 2022 | Abandon | 38 | 2 | 0 | No | No |
| 16353870 | Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies | March 2019 | December 2021 | Allow | 33 | 1 | 1 | Yes | No |
| 16333549 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | March 2019 | October 2022 | Allow | 43 | 2 | 1 | Yes | No |
| 16299022 | CRYOPRESERVED IN VITRO CELL CULTURE OF HUMAN PANCREATIC PROGENITOR CELLS | March 2019 | September 2022 | Allow | 43 | 3 | 0 | Yes | No |
| 16298360 | ApoO FOR USE IN A METHOD FOR TREATING CANCER AND VARIOUS PATHOPHYSIOLOGICAL SITUATIONS | March 2019 | March 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16296033 | Animal Models and Therapeutic Molecules | March 2019 | November 2021 | Allow | 32 | 1 | 1 | Yes | No |
| 16330774 | CRISP-SEQ, AN INTEGRATED METHOD FOR MASSIVELY PARALLEL SINGLE CELL RNA-SEQ AND CRISPR POOLED SCREENS | March 2019 | June 2022 | Allow | 40 | 3 | 1 | Yes | No |
| 16329915 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC GRANULOMATOUS DISEASE | March 2019 | June 2023 | Allow | 51 | 4 | 0 | Yes | No |
| 16330068 | NOVEL STEM CELL CARRIER AND METHOD FOR PREPARING THE SAME | March 2019 | September 2021 | Abandon | 30 | 2 | 1 | No | No |
| 16329376 | Genetically Modified Non-Human Animal With Human Or Chimeric PD-L1 | February 2019 | December 2021 | Allow | 33 | 3 | 1 | Yes | No |
| 16266724 | CALRETICULIN AND FUSION PROTEINS | February 2019 | August 2021 | Abandon | 30 | 2 | 1 | No | No |
| 16322248 | COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND SENSITIZATION OF TUMORS TO CHEMOTHERAPIES | January 2019 | February 2022 | Allow | 36 | 3 | 1 | No | No |
| 16261065 | IDENTIFICATION OF PORCINE XENOANTIGENS | January 2019 | July 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16257671 | NON-HUMAN PRIMATE INDUCED PLURIPOTENT STEM CELL DERIVED HEPATOCYTES AND USES THEREOF | January 2019 | September 2021 | Allow | 32 | 2 | 1 | No | No |
| 16248157 | ANASTASIS BIOSENSOR | January 2019 | March 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16247420 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 | January 2019 | August 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16247380 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 | January 2019 | July 2021 | Allow | 30 | 1 | 1 | No | No |
| 16317126 | GENE THERAPY | January 2019 | May 2022 | Allow | 40 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, SHIN LIN.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHEN, SHIN LIN works in Art Unit 1632 and has examined 1,028 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner CHEN, SHIN LIN's allowance rate of 53.1% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, SHIN LIN receive 2.33 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, SHIN LIN is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +59.8% benefit to allowance rate for applications examined by CHEN, SHIN LIN. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.4% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 43.7% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 87.7% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 74.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.3% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.5% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.